CRPBT can significantly down-regulate the phosphorylation of PI3K and AKT in liver cancer cells, up-regulate the Bax/Bcl-2 ratio, and inhibit the expression of MMP2/3, N-cadherin and Vimetin proteins. Here, BCL2 is linked to liver cancer.